Guillain-Barré syndrome (GBS) is characterized by rapidly evolving ascending 
weakness, mild sensory loss, and hyporeflexia or areflexia. Acute inflammatory 
demyelinating polyneuropathy was the first to be recognized over a century ago 
and is the most common form of GBS. Axonal motor and sensorimotor variants have 
been described in the last three decades and are mediated by molecular mimicry 
targeting peripheral nerve motor axons. Other rare phenotypic variants have been 
recently described with pure sensory variant, restricted autonomic 
manifestations, and the pharyngeal-cervical-brachial pattern. It is important to 
recognize GBS and its variants because of the availability of equally effective 
therapies in the form of plasmapheresis and intravenous immunoglobulins.